Repligen news

Company beat Q2 earnings estimates on both EPS (54 cents vs. 45 cents consensus) and revenue ($204.1M vs. $202M consensus). Raised full-year 2026 guidance for both revenue and EPS. Demonstrated strong growth across all business segments (filtration, chromatography, proteins up 50%, process analytics up 30%), improved margins (gross margin up 280 bps), and received Zacks Rank #1 Strong Buy rating with expectations for above-average returns.

Zacks Rank #1 (Strong Buy) rating with rising earnings estimates for 2026-2027 and consistent earnings beats (average 16.80% surprise). Stock has gained 10.3% year to date.

Featured as a leading company in the bioprocess automation market, well-positioned to capitalize on the growing demand for scalable biomanufacturing solutions.

Mentioned as a better-ranked biotech stock with Zacks Rank #1, but no direct connection to the main article content. Included only as comparative industry reference.

Stock gained 13.5% over the past month, outperforming Jazz Pharmaceuticals. Company reported 11.9% year-over-year revenue growth and improved EPS ($0.54 vs. $0.37 year-ago). Holds Zacks Rank #1 (Strong Buy) based on positive estimate revisions, indicating strong momentum.

Mentioned as a better-ranked biotech stock (Zacks Rank #1) with rising earnings estimates and consistent earnings beats, but not directly related to the main article content about flu vaccines.

Repligen holds a Zacks Rank #1 (Strong Buy) with rising earnings estimates for 2026-2027 and consistent earnings beats. Year-to-date gains of 7.6% reflect positive momentum in the biotech sector.

Identified as an emerging player gaining momentum by offering specialized filtration solutions in the rapidly growing bioprocess filtration market.

Peer company in bioprocessing services closed up 4.93%, gaining from increased sector activity and positive momentum in the life sciences and healthcare M&A space.